Search

everythinglearnresearchcommunity

for

Search:↓

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Pantethine may boost the immune system's ability to fight sarcoma.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Ritlecitinib is safe and may effectively treat alopecia areata.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

Baricitinib may effectively treat nail changes in alopecia areata.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

Tofacitinib helped a woman regrow hair with no major side effects.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Nephronectin is linked to worse breast cancer outcomes and helps cancer spread.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

Erlotinib can cause nonscarring hair loss and itchy skin.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Alpinetin helps grow hair by turning on hair stem cells and is safe for use.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.